Home » VWR Becomes Rep for RNAx's siRNA and shRNA Services in Europe

VWR Becomes Rep for RNAx's siRNA and shRNA Services in Europe

Jun 27, 2007
NEW YORK (GenomeWeb News) — RNAx said today that VWR will serve as a sales representative for its RNAi services in Europe.
 
Under the multi-year, co-exclusive agreement, researchers in Europe will be able to access automated siRNA and shRNA validation services at RNAx via their local VWR specialist service representative.
 
Financial terms of the agreement were not released.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Scan

Second One From Kite

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Worth the Price?

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Beyond Counting Tree Rings

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

This Week in Nature

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.

What's Popular?

In Gene Silencing/Gene Editing

  1. Majority of Genetics Professionals Supports Human Gene Editing, Stanford Survey Finds

  2. Broad, DuPont Pioneer Partner to Provide Non-Exclusive Licenses to CRISPR IP

Sponsorships

Privacy Policy.  Copyright © 2017 GenomeWeb LLC.  All Rights Reserved.